- Home
- OAKU vs MGX Comparison
OAKU vs MGX Comparison
Compare OAKU & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OAKU
- MGX
- Stock Information
- Founded
- OAKU 2022
- MGX 2018
- Country
- OAKU Canada
- MGX United States
- Employees
- OAKU N/A
- MGX N/A
- Industry
- OAKU Blank Checks
- MGX
- Sector
- OAKU Finance
- MGX
- Exchange
- OAKU Nasdaq
- MGX NYSE
- Market Cap
- OAKU 62.7M
- MGX 62.1M
- IPO Year
- OAKU 2023
- MGX 2024
- Fundamental
- Price
- OAKU $11.89
- MGX $2.43
- Analyst Decision
- OAKU
- MGX Strong Buy
- Analyst Count
- OAKU 0
- MGX 4
- Target Price
- OAKU N/A
- MGX $13.00
- AVG Volume (30 Days)
- OAKU 3.3K
- MGX 1.0M
- Earning Date
- OAKU 01-01-0001
- MGX 08-13-2025
- Dividend Yield
- OAKU N/A
- MGX N/A
- EPS Growth
- OAKU N/A
- MGX N/A
- EPS
- OAKU 0.00
- MGX N/A
- Revenue
- OAKU N/A
- MGX $45,263,000.00
- Revenue This Year
- OAKU N/A
- MGX N/A
- Revenue Next Year
- OAKU N/A
- MGX $3.97
- P/E Ratio
- OAKU $250,858.00
- MGX N/A
- Revenue Growth
- OAKU N/A
- MGX N/A
- 52 Week Low
- OAKU $10.92
- MGX $1.23
- 52 Week High
- OAKU $11.97
- MGX $4.92
- Technical
- Relative Strength Index (RSI)
- OAKU 69.68
- MGX 66.95
- Support Level
- OAKU $11.70
- MGX $1.98
- Resistance Level
- OAKU $11.97
- MGX $2.64
- Average True Range (ATR)
- OAKU 0.01
- MGX 0.23
- MACD
- OAKU 0.02
- MGX 0.04
- Stochastic Oscillator
- OAKU 71.11
- MGX 77.89
About OAKU Oak Woods Acquisition Corporation
Oak Woods Acquisition Corp is a a newly-incorporated blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more target businesses.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.